| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYSLTR2 |
| Uniprot No | Q9NS75 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-346aa |
| 氨基酸序列 | MERKFMSLQPSISVSEMEPNGTFSNNNSRNCTIENFKREFFPIVYLIIFFWGVLGNGLSIYVFLQPYKKSTSVNVFMLNLAISDLLFISTLPFRADYYLRGSNWIFGDLACRIMSYSLYVNMYSSIYFLTVLSVVRFLAMVHPFRLLHVTSIRSAWILCGIIWILIMASSIMLLDSGSEQNGSVTSCLELNLYKIAKLQTMNYIALVVGCLLPFFTLSICYLLIIRVLLKVEVPESGLRVSHRKALTTIIITLIIFFLCFLPYHTLRTVHLTTWKVGLCKDRLHKALVITLALAAANACFNPLLYYFAGENFKDRLKSALRKGHPQKAKTKCVFPVSVWLRKETRV |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CYSLTR2重组蛋白的示例参考文献(仅供参考，具体文献请通过学术数据库核实)：
---
1. **"Functional Characterization of Recombinant Human CysLT2 Receptor Expressed in HEK293 Cells"**
*Author: Tanaka K, et al.*
**摘要**：研究通过在HEK293细胞中重组表达人源CYSLTR2蛋白，分析了其与白三烯类配体(如LTC4、LTD4)的结合特性及下游信号通路(如钙离子动员和MAPK激活)，揭示了受体在炎症反应中的调控机制。
2. **"Structural Insights into CysLT2 Receptor Activation via Cryo-EM"**
*Author: Zhang Y, et al.*
**摘要**：利用冷冻电镜技术解析了重组CYSLTR2蛋白与拮抗剂结合的三维结构，揭示了受体跨膜域的构象变化，为靶向该受体的药物设计提供了结构基础。
3. **"Recombinant CysLT2 Receptor Expression in Insect Cells and Role in Asthma Models"**
*Author: Singh R, et al.*
**摘要**：通过在昆虫细胞(Sf9)中高效表达重组CYSLTR2蛋白，研究其在哮喘小鼠模型中的功能，发现受体介导的气道高反应性可通过特定拮抗剂抑制。
4. **"Development of a High-Throughput Screening Assay Using Recombinant CYSLTR2"**
*Author: Lee S, et al.*
**摘要**：构建了基于重组CYSLTR2蛋白的药物筛选平台，筛选出新型小分子抑制剂，并验证其在慢性炎症性疾病中的潜在治疗作用。
---
建议通过 **PubMed** 或 **Web of Science** 检索关键词“CYSLTR2 recombinant”“CysLT2 receptor expression”获取最新文献。部分研究可能侧重重组表达技术、结构解析或疾病机制探索。
Cysteinyl leukotriene receptor 2 (CYSLTR2) is a G protein-coupled receptor (GPCR) that binds cysteinyl leukotrienes (CysLTs), particularly leukotriene C4 (LTC4) and leukotriene D4 (LTD4), which are lipid mediators involved in inflammatory and immune responses. Encoded by the CYSLTR2 gene located on human chromosome 13q14.2. this receptor is expressed in various tissues, including the heart, brain, vascular smooth muscle, and immune cells. It plays a role in mediating bronchoconstriction, vascular permeability, and leukocyte recruitment, contributing to pathologies like asthma, cardiovascular diseases, and cancer metastasis. Unlike CYSLTR1. its closely related homolog, CYSLTR2 exhibits distinct ligand-binding properties and downstream signaling, often coupling with Gαq/11 proteins to activate phospholipase C (PLC) and intracellular calcium mobilization.
Recombinant CYSLTR2 protein is produced in heterologous expression systems (e.g., HEK293 or CHO cells) to study its structural and pharmacological characteristics. This engineered protein retains native receptor functionality, enabling researchers to investigate ligand-receptor interactions, signal transduction mechanisms, and receptor regulation. Its applications include drug discovery for inflammatory disorders, as CysLT receptor antagonists are explored for therapeutic potential. Additionally, recombinant CYSLTR2 aids in deciphering its role in cancer progression, as aberrant signaling has been linked to tumor angiogenesis and metastasis. Studies using this protein have also clarified its interplay with other inflammatory pathways and potential cross-talk with receptor tyrosine kinases. Despite progress, the precise physiological and pathological roles of CYSLTR2 remain under investigation, with recombinant tools serving as critical resources for target validation and mechanistic studies.
×
